Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

類似資料

• Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
  著者:: Taher, Ali, 等
  出版事項: (2009)
• Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
  著者:: Pathare, Anil, 等
  出版事項: (2009)
• Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study
  著者:: Taher, Ali, 等
  出版事項: (2011)
• Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
  著者:: Taher, Ali, 等
  出版事項: (2011)
• Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients
  著者:: Jaiswal, Shikha, 等
  出版事項: (2017)